Full Name
Jorge Reis-Filho
Job Title
Chief Strategy Officer and Operating Partner
Company
Foresite Labs
Speaker Bio
Jorge S. Reis-Filho is Chief Strategy Officer and Operating Partner at Foresite Labs and Venture Partner at Foresite Capital. Across these roles, he helps shape company-building, portfolio and investment strategy at the convergence of AI and biomedical science, translating advances into differentiated platforms and companies and advising and mentoring scientists and founders from venture formation through growth.
Jorge joined Foresite from AstraZeneca, where he served as Chief of AI for Science Innovation and led a cross-therapeutic team of oncology and biopharma AI, primarily focused on the development and deployment of multimodal foundation models, advanced data science approaches, and agentic AI frameworks to drive innovation throughout AstraZeneca’s pipeline and portfolio. Prior to joining AstraZeneca, Jorge consulted for Goldman Sachs Merchant Banking and Bain Capital, in addition to serving on the boards of directors and scientific advisory boards for several biotechnology companies, guiding strategy across precision medicine and AI.
Jorge earned a joint MD from the University of Porto, Portugal, and the Universidade Federal do Paraná, Brazil. He also earned a PhD in breast cancer molecular pathology from the Institute of Cancer Research and the Royal Marsden Hospital in London, where he rose to Team Leader and subsequently Professor and Chair of Molecular Pathology. In 2012, he joined Memorial Sloan Kettering Cancer Center in New York, becoming Chief of Experimental Pathology and Director of the Experimental Pathology Fellowship Program in 2016.
Author of more than 700 peer-reviewed papers, Jorge has defined molecular taxonomies for rare tumours, created a predictive classification of breast cancer, elucidated the causes and consequences of intra-tumour genetic heterogeneity, and pioneered technologies ranging from single-cell DNA sequencing of archival tissue to FDA-cleared computational pathology diagnostics. He is also the youngest individual ever elected Fellow of the Royal College of Pathologists by published works.
Jorge joined Foresite from AstraZeneca, where he served as Chief of AI for Science Innovation and led a cross-therapeutic team of oncology and biopharma AI, primarily focused on the development and deployment of multimodal foundation models, advanced data science approaches, and agentic AI frameworks to drive innovation throughout AstraZeneca’s pipeline and portfolio. Prior to joining AstraZeneca, Jorge consulted for Goldman Sachs Merchant Banking and Bain Capital, in addition to serving on the boards of directors and scientific advisory boards for several biotechnology companies, guiding strategy across precision medicine and AI.
Jorge earned a joint MD from the University of Porto, Portugal, and the Universidade Federal do Paraná, Brazil. He also earned a PhD in breast cancer molecular pathology from the Institute of Cancer Research and the Royal Marsden Hospital in London, where he rose to Team Leader and subsequently Professor and Chair of Molecular Pathology. In 2012, he joined Memorial Sloan Kettering Cancer Center in New York, becoming Chief of Experimental Pathology and Director of the Experimental Pathology Fellowship Program in 2016.
Author of more than 700 peer-reviewed papers, Jorge has defined molecular taxonomies for rare tumours, created a predictive classification of breast cancer, elucidated the causes and consequences of intra-tumour genetic heterogeneity, and pioneered technologies ranging from single-cell DNA sequencing of archival tissue to FDA-cleared computational pathology diagnostics. He is also the youngest individual ever elected Fellow of the Royal College of Pathologists by published works.
Speaking At
